BioDlink International Company Limited (HKG:1875)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.030
0.00 (0.00%)
At close: Mar 6, 2026
Market Cap3.11B +117.8%
Revenue (ttm)1.17B +9.6%
Net Income7.96M -19.0%
EPS0.01 -19.0%
Shares Out772.79M
PE Ratio391.48
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,110,800
Average Volume1,885,045
Open4.030
Previous Close4.030
Day's Range4.010 - 4.060
52-Week Range1.520 - 4.660
Beta0.21
RSI55.96
Earnings DateMar 18, 2026

About HKG:1875

BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 604
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1875
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements